Srikripa Devarakonda

Stock Analyst at Truist Securities

(0.68)
# 2437
Out of 5,370 analysts
70
Total ratings
36.96%
Success rate
1.52%
Average return
19 Stocks
Name Action PT Current % Upside Ratings Updated
INCY Incyte
Maintains: Hold
72 73
71.13 2.63% 10 May 27, 2025
ARVN Arvinas
Downgrades: Hold
21 11
7.38 49.05% 1 May 5, 2025
REGN Regeneron Pharmaceut...
Maintains: Buy
975 940
522.29 79.98% 7 Apr 30, 2025
BIIB Biogen
Maintains: Buy
210 199
131.07 51.83% 4 Apr 29, 2025
KROS Keros Therapeutics
Maintains: Buy
43 25
13.63 83.42% 5 Apr 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
60 76
54.66 39.04% 2 Mar 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
1029 1038
807.13 28.6% 4 Feb 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
211 217
190.7 13.79% 3 Feb 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
36 32
24.39 31.2% 1 Dec 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
33 50
14.66 241.06% 6 Nov 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
36 45
32.15 39.97% 4 Nov 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
54 53
46.85 13.13% 3 Nov 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
54 54
2.65 1937.74% 1 Sep 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
18 15
5.62 166.9% 7 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
36
11.87 203.29% 1 Jul 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
86 70
33.75 107.41% 4 May 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
80 60
n/a n/a 2 Aug 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
38
n/a n/a 3 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
50 34
n/a n/a 2 Jun 3, 2021